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Abstract 
Pathological accumulation of abnormally phosphorylated tau protein in astrocytes is a 
frequent, but poorly characterized feature of the aging brain. Its etiology is uncertain, but its 
presence is sufficiently ubiquitous to merit further characterization and classification, which 
may stimulate clinicopathological studies and research into its pathobiology. This paper aims 
to harmonize evaluation and nomenclature of aging-related tau astrogliopathy (ARTAG), a 
term that refers to a morphological spectrum of astroglial pathology detected by tau 
immunohistochemistry, especially with phosphorylation-dependent and 4R isoform specific 
antibodies. ARTAG occurs mainly, but not exclusively, in individuals over 60 years of age. 
Tau-immunoreactive astrocytes in ARTAG include thorn-shaped astrocytes at the glia 
limitans and in white matter, as well as solitary or clustered astrocytes with perinuclear 
cytoplasmic tau immunoreactivity that extends into the astroglial processes as fine fibrillar or 
granular immunopositivity, typically in gray matter. Various forms of ARTAG may coexist in 
the same brain and might reflect different pathogenic processes. Based on morphology and 
anatomical distribution, ARTAG can be distinguished from primary tauopathies but may be 
concurrent with primary tauopathies or other disorders. We recommend four steps for 
evaluation of ARTAG: 1) identification of five types based on the location of either 
morphologies of tau astrogliopathy: subpial, subependymal, perivascular, white matter, gray 
matter; 2) documentation of the regional involvement: medial temporal lobe, lobar (frontal, 
parietal, occipital, lateral temporal), subcortical, brainstem; 3) documentation of the severity 
of tau astrogliopathy; and 4) description of subregional involvement. Some types of ARTAG 
may underlie neurological symptoms; however, the clinical significance of ARTAG is 
currently uncertain and awaits further studies. The goal of this proposal is to raise awareness 
of astroglial tau pathology in the aged brain, facilitating communication among 
neuropathologists and researchers, and informing interpretation of clinical biomarkers and 
imaging studies that focus on tau-related indicators. 
 
Key words: aging; ARTAG; tau astrogliopathy; tau; 
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Introduction 
Tau is a microtubule-associated protein that binds to tubulin and promotes its polymerization 
and stabilization into microtubules. Tau isoforms, ranging from 352 to 441 amino acids, are 
generated by the alternative splicing of exons 2, 3, and 10 of the MAPT gene. The six 
isoforms differ from each other by the presence or absence of 29- or 58-amino acid inserts in 
the N-terminus domain and by the presence of either three (3R tau isoforms) or four (4R tau 
isoforms) tandem repeat sequences of 31 or 32 amino acids [24]. Mutations in the tau gene 
(MAPT) can cause hereditary frontotemporal dementia and associate with frontotemporal 
lobar degeneration (FTLD) [23, 26, 51, 63].  Following the description of a disorder in one 
family named ‘multiple system tauopathy with presenile dementia’ [62], the term tauopathy 
was introduced to refer to disorders in which tau protein deposition is the predominant feature 
[23]. Tauopathies are characterized by the accumulation of abnormal and hyper-
phosphorylated tau protein in the brain and are also classified as primary or secondary [32, 
37]. Tau pathology is characterized as 3R or 4R predominant or mixed 3R+4R type [12, 30, 
32]. Primary tauopathies are grouped also as FTLD-tau and comprise Pick disease (PiD), 
progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain 
disease (AGD), neurofibrillary tangle (NFT) predominant senile dementia (NFT-dementia or 
“tangle-only” dementia; now included in the category of PART, see below), and globular glial 
tauopathy (GGT) [32, 47]. In addition, many other diseases or conditions with diverse 
etiology, including Alzheimer disease (AD), may be associated with tau pathology [32]. The 
recently introduced term 'primary age-related tauopathy' (PART) encompasses neuronal 
changes previously considered as “normal aging” as well as NFT-dementia [14]. PART is 
distinguished from AD, largely by the absence or scarcity of amyloid (Aβ) plaques [14]. In 
aged individuals sex-dependent tau pathology, developing independently from AD has been 
also described in the hypothalamus [16, 54, 56]. Furthermore, chronic traumatic 
encephalopathy (CTE) is associated with a distinctive pattern of progressive neuronal and 
glial tau pathology [40-42]. 
  
The introduction of the Gallyas silver stain and particularly diagnostic tau 
immunohistochemistry led to the identification of astroglial tau pathology in the aging brain 
in people with or without AD-related changes, cognitive decline or movement disorders [5, 7, 
11, 21, 25, 31, 34-36, 38, 46, 57]. There have been attempts to classify these tau 
astrogliopathies [34], but there is lack of consensus as to how best to describe and categorize 
them. We recommend the term aging-related tau astrogliopathy (ARTAG) to describe the 
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spectrum of otherwise unclassified tau immunoreactivity in astrocytes (i.e., distinct from 
tufted astrocytes, astrocytic plaques, ramified astrocytes, or globular astroglial inclusions) 
mostly in aged individuals detected by tau immunohistochemistry using phosphorylation-
specific, conformation-specific, or isoform-specific (4R) anti-tau antibodies. Both ARTAG 
and PART affect predominantly the elderly, but PART is characterized by neurofibrillary 
degeneration that is largely restricted to the medial temporal lobe (MTL), basal forebrain, 
brainstem, and olfactory bulb and cortex [14]. PART thus describes neuronal tau pathology, 
while ARTAG focuses on astrocytic tau pathology. Whether PART and ARTAG belong to 
separate or shared pathogenic processes is unknown. 
 
We propose a four-step approach for the morphological classification of ARTAG. We 
anticipate that harmonizing the nomenclature and improving consistency in documentation of 
ARTAG is a necessary first step for defining diagnostic guidelines that will result in progress 
in clinicopathological correlation and investigation of the pathogenesis of ARTAG.  
 
Morphology of tau-immunoreactive astrocytes in primary tauopathies and CTE 
The defining lesions of tauopathies are intracellular aggregates of abnormal conformers of 
tau, consistently detectable by immunohistochemistry for phosphoepitopes (e.g., PHF1, CP13, 
and AT8), as well as epitopes to conformational epitopes (e.g., Alz50 and MC1) and tau 
isoform specific epitopes (e.g., 4R tau isoforms) [32]. Regardless of the tauopathy, astroglial 
tau inclusions are mostly 4R tau-immunopositive, although ramified astrocytes in PiD as well 
as occasional protoplasmic astrocytes in PSP may show 3R-tau immunoreactivity [21]. Tufted 
astrocytes are characteristic of PSP, and astrocytic plaques are signature lesions of CBD, 
while so-called ramified astrocytes have been described in PiD [15, 32]. In addition, 
astroglial, argyrophilic, and intracytoplasmic flame or thorn-shaped inclusions were described 
by Nishimura et al. in PSP [49]. Phosphorylation-dependent anti-tau antibodies are highly 
sensitive and label lesions that are not consistently detectable by silver impregnation methods, 
but may show variable ubiquitin or p62/sequestosome immunopositivity, such as the globular 
astroglial inclusions (GAI) of GGT [1], or the fine granular tau immunopositivity (some with 
‘bush-like’  appearance) of the astrocytes of AGD [11]. Some of the variation in the 
morphology of the immunolabeled structures was interpreted as representing stages of a 
process of aggregation and fibrillation, analogous to progression from pretangles to 
neurofibrillary tangles in AD [6, 11]. The concept of early-stage tau accumulation in 
astrocytes has also been discussed in relation to the changes in the basal ganglia in PSP [53]. 
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Finally, subpial and subependymal clusters of astrocytic tangles have been described in CTE 
[41]. 
 
Overview of astrocytic tau pathologies in the aging brain 
Both neuronal and glial tau pathology increases in frequency with age. The most frequent 
neuronal tau inclusions are neurofibrillary tangles, threads, and argyrophilic grains. Neuronal 
and glial inclusions resembling PSP pathology can be seen in the elderly, even without 
clinical evidence of PSP [17, 18, 34], but these lack the typical multisystem degeneration seen 
with PSP. Furthermore, tuft-shaped astrocytes have been described in a subgroup of elderly 
individuals, especially in association with Lewy body pathology, in a distribution resembling 
that of PSP [25]. Nevertheless, converging data emphasize the presence of a tau 
astrogliopathy that differs from tufted astrocytes or astrocytic plaques as a common finding in 
the elderly. Despite its high prevalence, there is a lack of consensus on whether these 
astroglial tau pathologies in the elderly are clinically relevant, even as a concomitant 
pathology that might lower an individual’s threshold for the development of clinical 
symptoms. Research in this field has been hampered by the variation in staining methods, tau 
antibodies, and the inconsistent nomenclature for astroglial tau pathologies. Importantly, 
hypertrophic astrocytes, as revealed by hematoxylin and eosin staining and 
immunohistochemistry for glial fibrillary acidic protein and excitatory amino acid transporter 
2 (EAAT2), are common in the elderly, and presumably represent a reaction to multiple types 
of injury. The location of such reactive astrocytes varies considerably among individuals [8, 
59]. Colocalization studies have indicated that glial fibrillary acidic protein-immunoreactive 
reactive astrocytes are not necessarily those that are also immunoreactive for tau pathology 
[19].   
 
Ikeda and colleagues were the first to describe tau-positive thorn-shaped astrocytes (TSA), 
which were similar in morphology to tau-positive astrocytes described by Nishimura et al. in 
PSP [49]) in the subpial or subependymal regions of the gray and white matter and frequently 
in the depths of gyri, as well as in the basal forebrain and brainstem, in aged individuals [27-
29]. TSA may occur in multiple conditions [13]. In comparison to the tufted astrocytes of PSP, 
TSA showed more voluminous perinuclear cytoplasm and their processes are often thicker 
and shorter [27]. TSA were only occasionally found in the deep cortical layers. The authors 
noted that anti-ubiquitin antibodies do not label TSA. They interpreted TSA as a non-specific 
finding and found no relationship between the number of TSA and the severity of 
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neurofibrillary changes. Argyrophilic, tau-positive subpial and perivascular structures were 
also described as common TSA [27-29].  
 
Schultz et al. reported a high prevalence of TSA in the aged human MTL, particularly the 
anterior MTL, at the level of the amygdala [57]. TSA were absent in individuals under 60 
years, but affected almost half of brains from those over 75 years [57]. Indeed, another study 
also failed to find this type of tau astrogliopathy in younger individuals [33]. Schultz et al. 
[57] commented that tau immunopositivity was not confined to the thorn-shaped proximal 
processes of astroglia, but also presented as thread-like processes in the neuropil. They found 
that immunolabeling with AT8 was the most sensitive for demonstrating the TSA, while 
silver staining was less consistent [57]. They also speculated that the preferential subpial and 
perivascular location could be a result of exposure to CSF or to extravasated plasma proteins 
due to defects in blood-brain barrier permeability commonly seen in aging and 
neurodegeneration [36, 57]. Interestingly, a similar distribution of TSA was reported in aged 
baboons [55]. A study by the MRC-CFAS group confirmed the findings of Schultz et al. and 
added that the TSA could be less commonly observed in the vicinity of neuronal cell bodies in 
gray matter areas such as amygdala and dentate gyrus [36]. Also, this study documented the 
4R tau nature of TSA [36]. Variable staining for Gallyas and p62 suggest that some of these 
astrocytes accumulate tau in a fibrillar state [34-36, 38, 46]. Uchikado et al. also reported that 
the frequency of TSA increased with age and was independent of AGD [66]. All studies agree 
that the burden of TSA is independent of AD pathology, AGD, coiled bodies, dementia status 
at death, or presence of the APOE ε4 allele [27, 28, 36, 57, 66]. These studies, however, were 
limited to evaluation of the MTL and did not take account of cortical and subcortical tau 
astrogliopathy. Few studies reported tau immunopositivity in glial cells in AD cases with 
prolonged duration of the disease [5, 48, 68]. Finally, a report on NFT-dementia mentioned 
the presence of astrocytic tau pathology in white matter and cortex [31]. 
 
The possibility that TSA may have clinical significance was first raised by Munoz and 
colleagues [46]. They used the term ”argyrophilic thorny astrocyte clusters (ATACs)” and 
observed them in the frontal, temporal, and parietal cortices and in subcortical white matter in 
a cohort of patients with nonfluent variant of primary progressive aphasia associated with AD 
pathology [46]. Subsequent reports also linked TSA to symptomatology, although not all 
found an association of ATACs with focal neurological syndromes [9, 43]. Munoz and 
colleagues noted ATACs in the white matter without discernible changes in sections stained 
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for myelin. ATACs did not show a consistent topographic relationship to amyloid deposits, 
NFTs, or reactive astrogliosis [46]. Interestingly, focal glial tauopathy, interpreted as PSP-
type, associated with progressive aphasia was reported by Wakabayashi et al. [67]. These 
observations suggested that TSA-like astrocytes might be detected not only in a 
subependymal or subpial location. 
A peculiar constellation of tau pathology was documented in a subset of patients with 
dementia [35]. The most characteristic feature was a tau astrogliopathy, which was described 
as diffuse granular tau immunoreactivity in astrocytic processes [35]. The study emphasized 
additional neuronal pathologies, including threads and diffuse neuronal cytoplasmic tau 
immunoreactivity (pretangle-like). A further study distinguished four different patterns based 
on the anatomical distribution of the tau astrogliopathy and its combination with neuronal tau 
pathology, characterized mostly by pretangles and scattered threads [34]: 1) medial temporal 
lobe type (Group I); 2) amygdala type (Group II); 3) limbic-basal ganglia-nigral type with 
neuronal tauopathy (Group III); and 4) hippocampus-dentate gyrus-amygdala type with 
neuronal tauopathy (Group IV). Some of these might represent stages of the same process 
whereas other might be different. Nevertheless, evaluation of tau astrogliopathy in several 
anatomical regions indicated that in some cases astroglial tau pathology in the elderly extends 
beyond the MTL to involve the frontal and parietal cortices, striatum, substantia nigra, and 
medulla [34]. The morphology of tau astrogliopathy in these studies, was reminiscent of that 
reported by Munoz et al. as ATACs [46], although extension of the immunoreactivity into the 
astrocytic processes was emphasized [34, 35]. Distinct accumulation of TSA in the dentate 
gyrus of the hippocampus was also recognized [34, 36]. Mathematical modeling of 
hippocampal tau immunolabeling patterns suggested that some forms of tau astrogliopathy in 
the elderly involve hippocampal subregions in a different pattern from that of primary 
tauopathies [44]. Ferrer et al. [21, 38] showed that the biochemical signature of astroglial tau 
pathology in the elderly in both white and gray matter differed from that of other astrocytic 
tau pathologies in primary tauopathies. Specifically, astroglial tau pathologies in the white 
matter and gray matter in aging brains were not consistently detectable using phospho-
specific anti-tau antibody Ser262 or conformational tau modifications at amino acids 312 to 
322 (MC1), or tau truncated at aspartic acid 421 (tau-C3) [21, 38]. 
 
In addition, isolated tufted astrocytes were reported in the occipitotemporal gyrus in an 
elderly, population-representative cohort [36], and a tauopathy with tufted, thorny, fibrous, 
and protoplasmic forms of astrocytic pathology was described by Beach et al. [7], in a series 
	 11	
of cases with hippocampal sclerosis and also in a community-based study [34]. Sakai et al. 
[52] reported prominent subcortical white matter astrocytic tau pathology in brains from two 
elderly patients in whom CBD was considered. In a study on cervical spondylotic 
myelopathy, AT8 immunohistochemistry revealed tau-positive, neuropil threads, astrocytic 
foot-like perivascular or subpial structures, and glial cells with short and thick processes, 
which the authors termed TSA [58]. Interestingly, prominent tau astrogliopathy may be seen 
in familial disorders without MAPT mutation [20].  
 
In summary, tau-immunoreactive astrogliopathy in the elderly represent a spectrum of 
morphological abnormalities including those originally described as TSA (plump, perinuclear 
cytoplasmic immunoreactivity) and additional fine granular tau immunoreactivity extending 
into the astrocytic processes in the gray matter. These two morphologies can be present in the 
same brain. TSA may be seen in subpial, subependymal, or perivascular areas, as well as in 
the white and gray matter, while the fine granular immunoreactivity is seen in the gray matter. 
Most likely, the different tau-immunoreactive astroglial morphologies in different locations in 
the aging brain, with or without clinical correlation, reflect different pathogenetic events. We 
propose the umbrella term ARTAG to encompass all of these, with or without accompanying 
morphological features of other neurodegenerative disorders, including PSP, CBD, PiD, 
GGT, PART, AD, AGD, and Lewy body pathology. Some clinicopathological studies suggest 
that ARTAG may present clinically with focal symptoms like aphasia when circumscribed to 
a smaller number of regions [46], whereas, in cases with widespread pathology dementia with 
or without parkinsonism might be the clinical presentation [34, 35]; on the other hand, studies 
focusing only on the MTL have found no relationship between ARTAG and cognitive 
impairment or dementia [36].   
 
Differential diagnosis 
We provide the following operational criteria for the six well-defined tau immunoreactive 
astrocytic cytopathologies seen in primary tauopathies and ageing brain as follows (see 
comparison in Table 1 and Fig. 1): 
1) Tufted astrocytes: star-like tufts of tau-positive radiating fibers. The dense tau 
immunoreactive tufts are detected in the proximal part of the astrocytic processes, often 
usually in a symmetrical fashion. They are localized to the gray matter (mostly basal ganglia 
and neocortex). 
2) Astrocytic plaques: focal and densely tau-immunoreactive stubby dilatations of distal 
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processes of astrocytes giving a senile-plaque-like appearance without amyloid core. They are 
localized to the gray matter (mostly basal ganglia and neocortex). 
3) Ramified astrocytes: tau immunoreactivity occupying mostly the perikarya and ramifying 
into the cell processes usually localized to one side of the cell giving the appearance of 
eccentric nuclei of the astrocyte. They are localized to the gray matter and to the white matter 
in neocortices with severe neuronal loss.  
4) Globular astroglial inclusions: tau immunoreactive distinct globules (up to the size of the 
astroglial nucleus; 1-5 µm) and dots (1-2 µm) in the perikarya and proximal parts of 
astrocytic processes, found in gray matter.  
5) Thorn-shaped astrocytes (TSA): tau immunoreactivity is localized in astrocytic perikarya 
with extension into the proximal parts of the astrocytic processes, with inclusions also in the 
astrocytic endfeet at the glia limitans around blood vessels and at the pial surface. The 
processes are thick and short and reminiscent of thorns. They are preferentially found at 
subpial and perivascular locations, as well as in the white matter and less often as clusters in 
the gray matter.  
6) Granular or fuzzy tau immunoreactivity in processes of astrocytes (GFA): fine granular 
immunoreactivity of branching processes with a few dilations of gray matter astroyctes. The 
perinuclear soma is densely immunoreactive in most of these astrocytes. 
 
The two major cytomorphologies of ARTAG (i.e., TSA and GFA) may accompany 
tauopathies or other neurodegenerative disorders, but ARTAG should be distinguished from 
the more specific astrocytic lesions that are characteristic of primary tauopathies. To 
understand the frequency and relevance of ARTAG we recommend documenting ARTAG as 
an additional feature in primary tauopathies. It must be noted, that the astroglial tau 
immunoreactivity described by Botez et al. in the amygdala of AGD [11] fits best with the 
GFA now included as a form of ARTAG. Indeed, astrocytic tau pathology is variably seen in 
AGD [22]. Therefore, it is helpful to comment whether in a case of AGD additional ARTAG 
is present. Furthermore, there are other tau-related disorders with astrocytic tau pathology. 
For instance, astrocytic tau pathology is also a component of CTE [40-42]. CTE is associated 
with a history of repetitive concussive or subconcussive brain trauma and is characterized by 
widespread accumulation of hyperphosphorylated tau in NFTs and astrocytes, which have 
similarity to TSA seen in ARTAG [41]. ARTAG has features that overlap those of CTE, 
including the accentuation of tau pathology around small cerebral vessels and in subpial and 
periventricular areas. On the other hand, tau pathology, including neuronal and astroglial, in 
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CTE is more abundant in the depths of the convexity cerebral sulci, especially in early stages 
[41], an aspect that  has not been reported in tau astrogliopathy in the aging brain [29, 34-36, 
46, 57]. It is possible that CTE pathology has been considered to be age-related 
astrogliopathy, especially for lesions in the MTL, which can be severely affected in more 
advanced stages of CTE [42]. The characteristic patchy lesions at depths of cerebral sulci 
were not recognized as a specific morphological feature of CTE in earlier studies. Finally, 
tufted astrocytes in PSP, astrocytic plaques in CBD, globular astrocytic inclusions in GGT, 
and ramified astrocytes in PiD are distinct from tau-immunoreactive astrocytes in the gray 
matter in ARTAG (see Table 1).  
 
These observations raise the possibility that ARTAG affects distinct astrocytic populations to 
those in established primary tauopathies. Ikeda and colleagues noted that the distribution of 
TSA was coexistent with prominent subpial and subependymal gliosis [29]. Corpora 
amylacea, which are heavily invested by reactive astrocytes, also share this distribution. 
Importantly, these astroglial populations of the “glia limitans” share common features with 
fibrous astrocytes, which predominate in the white matter and subpial zone [8] and with a 
subset of astrocytes in the gray matter [61], where ARTAG can be also observed. In contrast, 
astrocytic tau pathologies in CBD or PSP involve protoplasmic astrocytes and are 
independent of reactive astrogliosis [19, 65]. A few studies report association of glial 
fibrillary acidic protein and AT8 immunoreactivity in subpial but also in gray matter 
localization of tau astrogliopathy in elderly brains [35, 36]. Protoplasmic and fibrous 
astrocytes differ substantially in their glutamate uptake capabilities and capacity and have 
very different degrees of coupling, which are important with regard to their respective 
calcium wave signals, resting membrane potentials, potassium buffering, glutamate 
metabolism, exchange of second messengers, metabolites, and other signaling intermediates 
between cells [50]. In addition to these differences, reaction of astrocytes varies considerably 
between distinct diseases of the nervous system [60]. It is these differences that may be of 
pathogenetic relevance to the morphologic diversity of astrogliopathy in ARTAG. 
 
Evaluation of ARTAG 
Inconsistency in assessing, describing and documenting ARTAG has impeded research and 
limited our understanding of the significance of this pathology. It is not clear whether the 
different patterns of anatomical involvement represent a continuum or distinct abnormalities 
with different causes. Most previous studies have focused on the MTL, but more widespread 
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involvement is possible [34, 35]. The relative frequency of ARTAG limited to MTL as 
opposed to more widespread tau astrogliopathy remains unclear.  Potential etiologies are not 
known, although defective function of the blood-brain barrier [57], metabolic encephalopathy, 
neurodegenerative pathologies, hypoperfusion associated with aging, AD, or vascular 
dementia [39, 64], and even repeated minor trauma with possible genetic risk factors may 
play a role. Clinical, imaging and neuropathological data related to these aspects need to be 
documented precisely to allow a better understanding of the pathogenesis of ARTAG [47]. A 
method is needed to describe morphologies that can be widely accepted and reproducible. As 
silver impregnation methods are difficult to standardize and immunohistochemistry for 
ubiquitin and p62 does not demonstrate all forms of tau cytopathology, optimal 
characterization of ARTAG requires the use of immunohistochemistry for phosphorylated 
tau. The most widely used phosphorylation-dependent anti-tau antibodies that have allowed 
characterization of ARTAG to date include: AT8 (pSer202/Thr205; available from different 
commercial sources), CP13 (Ser202; Peter Davies, Litwin-Zucker Research Center for The 
Study of Alzheimer’s Disease and Memory, Manhasset, NY, USA) and PHF-1 or AD2 
(Ser396/Ser404; Peter Davies, NY, USA for PHF-1 or commercial sources for AD2s). Other 
antibodies that may prove useful in the characterization of ARTAG include those specific for 
tau phosphorylated at Thr181, Ser202, Ser214, Ser396, Ser422, N-terminus region epitope-
specific, 4R tau isoform-specific, and some conformation-dependent antibodies such as Alz50 
(but not MC-1) [21, 35, 38].  
 
Recommendations for sampling and staining are as follows: 
- Preliminary screening for ARTAG should include tau-immunohistochemistry (antibodies 
AT8, CP13, AD2 or PHF-1 are recommended) on two sections representative of the MTL 
(i.e., amygdala and hippocampus at the level of the lateral geniculate body). These regions 
are vulnerable to TSA and GFA. 
- If tau astrogliopathy is noted in the screening section, a systematic characterization of 
ARTAG will require analysis involving additional areas of the frontal, parietal, lateral 
temporal, and occipital cortices, as well as anterior and posterior portion of the basal 
ganglia, thalamus, midbrain at the level of substantia nigra, pons at the level of locus 
coeruleus, and medulla oblongata.  
- In cases where focal cortical symptoms are reported, further cortical areas corresponding to 
the clinical symptoms or signal alterations detected in MRI should also be evaluated. 
 
	 15	
ARTAG should be considered when detecting either or both of the two cytomorphologies: TSA 
or GFA. As such, we propose the following four-step characterization TReSS algorithm (Table 
2): 
Type? Regional involvement? Severity? Subegional involvement?  
 
• First: Identify the morphologic and distribution types of ARTAG based on parenchymal 
localization of TSA and GFA (note that combination of these types is generally the rule):  
1) Laminar subpial TSA (Fig. 2a): plump perinuclear cytoplasmic tau 
immunoreactivity in astrocytes in subpial locations. It is important to note whether this 
is more pronounced in the sulcal depths in the convexity cerebral cortices, as in CTE.  
2) Subependymal TSA: plump perinuclear cytoplasmic tau immunoreactivity in 
astrocytes in subpial or subependymal locations (Fig. 2b).  
3) Perivascular TSA: plump cytoplasmic immunoreactivity with tau-immunoreactive 
astrocytic processes around vessels (Fig. 2c) in the gray or white matter. 
4) White matter TSA: astrocytes in the subcortical white matter that show plump 
cytoplasmic immunoreactivity (Fig. 2d). Note that in the white matter these usually 
form small clusters (>3 astrocytes) and that it may extend into the adjacent gray matter 
as described for ATAC [46]. 
5) Gray matter GFA: solitary (one or two/20x field) (Fig. 2e, f) or clustered (Fig. 2g, 
h) GFA (three or more/20x field) with fine granular immunopositivity of the 
cytoplasmic processes (GFA), with plump perinuclear cytoplasmic tau 
immunoreactivity. Less frequently, TSA can be also seen in the gray matter. 
 
It must be noted that tau immunohistochemistry occasionally decorates astrocytes at 
the border of chronic vascular lesions in young and aged individuals. Therefore, this 
lesion-asssociated tau astrogliopathy is important to document, but is not considered 
an aging related astrogliopathy. 
 
• Second: Identify involvement of gross anatomical regions:  
A) MTL  
B) Lobar 
C) Subcortical  
D) Brainstem  
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Although the most frequently involved region is the MTL, involvement of further 
regions should be recognized. Moreover, MTL is important for comparison with 
neuroimaging data on MTL atrophy. 
 
• Third: Document the severity of ARTAG pathology in the region or subregion (see step 
four) examined. ARTAG may appear in focal clusters or in a widespread distribution. We 
propose documentation as to whether ARTAG involves only 1) occasional or 2) 
numerous astrocytes. If the latter, the focal clusters or widespread distribution should be 
noted. Semiquantitative scoring for ARTAG will need to be refined.  
 
• Fourth: Map subregional involvement to promote future exploration and scientific 
discovery related to ARTAG. These are the subdivisions within the gross anatomical 
regions of the second step and include the following (Table 3; examples are shown in Fig. 
3):  
- amygdala and hippocampus, inferior temporal gyrus for MTL 
- frontal, parietal, occipital, lateral temporal (middle and superior gyrus) for lobar 
- caudate nucleus, putamen, nucleus accumbens, globus pallidus, thalamus, basal 
forebrain for subcortical 
- mesencephalon, pons, medulla oblongata for brainstem 
 
It should be noted whether ARTAG is associated with features of a particular neurodegenerative 
disorder, or with other disease (cerebrovascular, inflammatory, metabolic, etc.) followed by the 
description of the type and major regional involvement. 
 
Some examples for the diagnostic reporting are provided as follows: 
1) Examples for pure types: 
a. ARTAG subpial type;  
Region: MTL;  
Subregion: hippocampus, inferior temporal cortex;  
Extent: numerous astrocytes and widespread distribution 
b. ARTAG subependymal type;  
Region: Subcortical;  
Subregion: lateral ventricle;  
Extent: occasional 
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2) Examples for combinations: 
 a. ARTAG gray matter type;  
Region: MTL and subcortical;  
Subregion: inferior temporal cortex and nucleus accumbens;  
Extent: numerous astrocytes in focal clusters  
plus  
  ARTAG white matter type;  
Region: MTL;  
Subregion: hippocampus, periamygdala white matter, and temporal;  
Extent: numerous astrocytes with widespread distribution; 
 
b. ARTAG perivascular type; 
Region: lobar and subcortical; 
Subregion: frontal cortex and striatum;  
Extent: occasional 
plus 
  ARTAG white matter type;  
Region: MTL and lobar;  
Subregion: lateral temporal, frontal, and parietal lobes;  
Extent: numerous astrocytes in focal clusters. 
 
For example, the cases described by Munoz et al. [46] would be summarized in the diagnostic 
report as: ARTAG gray and white matter type; region: MTL and lobar; extent: numerous in 
focal clusters. For research purposes, the subregional involvement should be added as: gyrus 
ambiens, parahippocampal gyrus, fusiform gyrus, inferior, middle, and superior temporal gyri, 
frontal dorsolateral and orbitofrontal cortices, cingulate gyrus, and inferior parietal lobe. The 
cases described by Kovacs et al. [35] could be summarized as ARTAG gray matter type; 
region: MTL, lobar, subcortical, and brainstem; extent: numerous in focal clusters; plus white 
matter type; region: MTL; extent: numerous and widespread; with further details on the 
subregional involvement. The cases discussed by Santpere and Ferrer [53] as early PSP-like 
astrocytic changes also represent ARTAG with additional features of concomitant PSP-type 
pathology (i.e. cases 4 and 5).  
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Summary 
 
ARTAG describes a spectrum of astroglial tau pathologies detected mainly in the elderly 
represented by TSA and GFA, which are distinct from astroglial lesions of primary 
tauopathies (i.e. tufted astrocytes, astrocytic plaques, ramified astrocytes, or globular 
astroglial inclusions). The frequency of ARTAG varies depending on the type: subpial, 
subependymal, and perivascular types are more frequent, while gray matter and cerebral white 
matter types might be less common. The etiology of different types might be different; 
however, all appear mostly associated with aging. Although documented in several 
publications, there is a lack of consensus on how ARTAG should be recorded and interpreted. 
Here we propose steps for a systematic characterization with the expectation that this will 
improve communication about and understanding of this condition, including its relation to 
other brain pathologies and clinical symptoms. This approach has the potential to help in 
several respects: 
1) It will facilitate communication between neuropathologists and 
researchers.  Revisiting and standardizing the terminology should help to move the 
field forward. It will also increase awareness of this pathology, which is under-
recognized and under-studied. 
2) A better differentiation of ARTAG types may help with assessing their relationship 
to other tauopathies.  This may be particularly important in the context of CTE-related 
tau pathologies. Furthermore, this may help better understanding of differences in the 
pathogenesis of ARTAG types. 
3) A regular system for typing and grading of ARTAG should facilitate comparisons 
between different centers, and the pooling of information in harmonized 
clinicopathological studies. These will potentially pave the way towards mechanistic 
insights and genetic studies into their pathogenesis.   
4) Understanding the nature of ARTAG may help in the interpretation of clinical 
biomarker and imaging studies. 
 
Development of such a common concept (Fig. 4) and nomenclature that allows comparisons 
across studies and aggregation of data for large scale multi-institutional analyses is imperative 
in order to understand the phenomena and clinical implications of ARTAG. Future studies 
should also aim to re-evaluate these observations to validate this approach and to develop a 
concise classification of ARTAG for diagnostic neuropathology. To reach this goal, 
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paradigms will need to be designed for ARTAG along the lines used to standardize evaluation 
and diagnostic criteria for tau, amyloid and α-synuclein and other major pathologies [2-4, 10, 
45].  Subsequently, it will be possible to evaluate inter-rater reliability of the proposed 
evaluation and eventually to merge clinical and pathologic data from multiple centers to 
determine practical significance of ARTAG. At this preliminary stage, however, our 
recommendation is limited to an evaluation strategy focusing primarily on common 
nomenclature and classification of aging related astrogliopathy.  
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Table 1. Operational criteria for the six well-defined tau-immunoreactive astrocytic 
cytopathologies seen in primary tauopathies and aging-related tau astrogliopathy 
(ARTAG))(see also Fig.1). GM: gray matter; WM: white matter; SP: subpial; SE: 
subependymal; PV: perivascular. In the column "Reported” those diseases are mentioned, 
where there are literature reports of the specific astrocytic tau pathologies. PSP: progressive 
supranuclear palsy; CBD: corticobasal degeneration; CTE: Chronic Traumatic 
Encephalopathy; PiD: Pick disease; GGT: globular glial tauopathy; AGD: argyrophilic grain 
disease. For Gallyas silver staining: + indicates consistently detectable; -/+ indicates variably 
detectable (for GFA the soma may be variably positive but the processes not); - indicates 
usually not detectable.  
 	 Characteristic immunoreactivity 	 	 		 	 Astrocytic processes 	 	 	
Name Soma Proximal Distal  Gallyas Reported Location 
a. Primary 
tauopathy-
related 
astroglial tau 
pathology 
      
Tufted 
astrocytes 
relatively 
spared 
dense tufts: 
usually 
symmetric 
no + PSP GM 
Astrocytic 
plaques spared no 
stubby 
dilatations + CBD GM 
Globular 
astroglial 
inclusions 
dense: filled 
with globules 
1-5 µm 
globules 
1-2 µm 
globules - GGT GM 
Ramified 
astrocytes 
dense: 
localized to 
one side 
dense 
ramifications: 
usually 
asymmetric 
no + PiD 
GM,  
WM/GM 
junction 
b. ARTAG-
related 
astroglial tau 
pathology 
      
Thorn-shaped 
astrocytes 
(TSA) 
dense: thorn 
or flame 
shaped 
short and thick no -/+ 
with or 
without 
PSP, AGD, 
AD, CTE, 
other 
GM, 
WM, SP, 
SE, PV 
Granular or 
fuzzy 
astrocytes 
(GFA) 
dense: 
perinuclear 
accumulation 
fine or fuzzy 
granular  
fine 
granular -/+ 
with or 
without 
AGD 
GM 
 
 
 
 
	 26	
Table 2. Evaluation of aging-related tau astrogliopathy (ARTAG). TSA: thorn-shaped 
astrocyte; GFA: granular /fuzzy astrocyte; AP: astrocytic plaque; TA: tufted astrocyte; RA: 
ramified astrocyte; GAI: globular astroglial inclusions. 
 
Requires: 
Presence of thorn-shaped astrocytes (TSA) and/or solitary or clustered astrocytes with plump 
cytoplasmic tau immunoreactivity that extend into the astroglial processes as fine granular 
immunopositivity (GFA) distinguishable from AP, TA, RA, and GAI. 
Four-step characterization of ARTAG: 
	
Step 1: Distinguish types according to the location: 
	
 Subpial 
	
 Subependymal 
	
 Gray matter 
	
  White matter 
	
  Perivascular 
	
Step 2: Describe major anatomical distribution  
	
 Medial temporal lobe 
	
 Lobar 
	
 Subcortical 
	
 Brainstem 
	
Step 3: Document the severity of ARTAG  
	
 Occasional 
	
 Numerous 
	
  - Focal 
	
  - Widespread 
	
Step 4: Map subregional involvement and extent (see Table 3) 
Ancillary studies:  
- Description of additional tau pathologies in specific anatomical regions: 	 •       Neurofibrillary degeneration 	 •       Neuropil threads 	 •       Diffuse cytoplasmic neuronal tau immunoreactivity (“pretangles“) • Argyrophilic grains 	 •       Dystrophic neurites around or within amyloid plaques 	 •       Oligodendroglial tau immunoreactivity  
- Characterization of tau phosphorylation, conformation, truncation, nitration, ubiquitination, 
immunohistochemistry for 4R and 3R tau; ultrastructural study; genetic studies (MAPT and other 
genes associated with neurodegeneration)  
- Description of concomitant neurodegenerative and non-neurodegenerative pathologies 
- Description of relation to lesions (”perilesional” astrocytic tau immunoreactivity), to corpora 
amylacea, and Rosenthal fibers 
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Table 3. Description of aging-related tau astrogliopathy (ARTAG) based on the type and distribution of astrocytic tau pathology. 
MTL: medial temporal lobe; Gy: gyrus; GP: globus pallidus; Caud/Put: Caudate and Putamen; Dent Gyr: dentate gyrus; Medulla obl.: medulla 
oblongata; Aq: Aqueduct; LV: lateral ventricle; 3V: 3rd Ventricle. *: in the case of focal cortical symptoms the anatomical area with clinical 
relevance should be noted additionally. Combinations of subtypes should be expected and described.  
 
Diagnostic screening   
		 		
Clinicopathological correlation and studies on pathogenesis 
(research) 
STEP 1   STEP 2   STEP 3    è    STEP 4 
Type è 
Major 
anatomical 
involvement 
è Severity   è   Detailed regional distribution and extent of ARTAG 
Subpial è 
MTL è 
occasional  
or  
numerous 
 (focal/widespread) 
  è   Inf. Temporal Gy Hippocampus Amygdala   
Lobar è   è   Frontal Parietal Occipital Lateral temporal 
Subcortical è   è   Basal forebrain -  -   
Brainstem è   è   Mesencephalon Pons Medulla obl   
Subependymal è 
MTL è   è   Temporal horn       
Lobar è   è   LV: Frontal horn LV: Occipital horn     
Subcortical è   è   LV: Caudate 3V: Thalamus      
Brainstem è   è   Aq/Mesencephalon Aq/Pons Aq/Medulla obl.   
Gray matter è 
MTL è   è   Inf. Temporal Gy Hippocampus  Amygdala   
Lobar* è   è   Frontal Parietal Occipital Lateral temporal 
Subcortical è   è   Accumbens Caud/Put GP Basal forebrain 
Brainstem è   è   Substantia nigra Pons Medulla obl.   
White matter è 
MTL è   è   Inf. Temporal Gy Hippocampus Amygdala   
Lobar* è   è   Frontal Parietal Occipital Lateral temporal 
Subcortical è   è   Internal capsule Subinsular Pencil fibers   
Brainstem è   è   Cerebral pedunculi Pyramids Midline   
Perivascular è 
MTL è   è   Inf. Temporal Gy Hippocampus Amygdala   
Lobar è   è   Frontal Parietal Occipital Lateral temporal 
Subcortical è   è   Accumbens Caud/Put GP Basal forebrain 
Brainstem è   è   Mesencephalon Pons Medulla obl.   
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Figure legends 
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Figure 1. Comparison of tau (using AT8 antibody) immunoreactivities seen in primary 
tauopathies with those observed in aging-related tau astrogliopathy (ARTAG).  
 
Figure 2. Representative photomicrographs of ARTAG types. 
Plump cytoplasmic tau immunoreactivity of astrocytes and tau-positive lining in subpial (a) 
and subependymal (b) location. Perivascular-type: tau-immunoreactive astrocytic processes 
arranged around vessels (c). White matter (WM)-type: Astrocytes in the subcortical white 
matter with plump cytoplasmic immunoreactivity (d). Gray matter (GM)-type: Single-
appearing (e, f) or clusters  (g, h) of astrocytes with fine granular tau immunoreactivity in the 
processes without (e) or with (f) plump perinuclear cytoplasmic tau immunoreactivity.  
The bar shown in “a” represents 30 µm for a, b, f; 50 µm for d, e, h; and 100 µm for c, g. 
 
Figure 3. Representative images of different anatomical regions showing ARTAG.  
a: Temporal cortex and white matter (WM); b: Dentate gyrus (gray matter-type cluster 
enlarged in the right); c: Amygdala; d: Frontal cortex (gray matter-type single); e: Nucleus 
accumbens (gray matter-type clusters and single forms); f: Substantia nigra; g and h: medulla 
oblongata (IO: inferior olive; ML: medial lemniscus; n. XII: hypoglossal nucleus). 
The bar shown in “a” represents 150 µm for a, b; 100 µm for the right inset in b, and c-h. 
 
Figure 4. Summary of the concept of ARTAG. 
Four distinct astroglial tau pathologies are seen in primary tauopathies: tufted astrocytes (TA), 
astrocytic plaques (AP), globular astroglial inclusions (GAI), and ramified astrocytes (RA). 
Rarely there may be slight overlap of these morphologies but predominance of a type is 
significantly associated with one of the specific primary tauopathies. ARTAG is characterized 
by two different morphologies: thorn-shaped astrocytes (TSA) and fine granular 
immunoreactivity in astrocytic processes (granular/fuzzy astrocytes: GFA); these are seen in 
the subpial (SP), subependymal (SE), perivascular (PV) areas, and in the white (WM) and 
gray matter (GM). TSA and GFA may be present in the same brain together. Other 
neurodegenerative diseases (NDDs) may coexist with ARTAG or with primary tauopathies. 
 
